Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Stroke 1 Recurrence 1 Ovarian Neoplasms 1 Neurologic Manifestations 1 Melanoma 1 Margins of Excision 1 Malignant Solid Neoplasm 1 Malignant Female Reproductive System Neoplasm 1 Inflammatory Breast Neoplasms 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Communication 1 Colorectal Neoplasms 1 Caregiver Burden 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1 Brain Neoplasms 1 Brain Injuries, Traumatic 1 Brain Injuries 1 Advanced Malignant Solid Neoplasm 1

Interventions

Nivolumab 21 pembrolizumab 19 Ipilimumab 14 Specimen Handling 12 Magnetic Resonance Spectroscopy 7 Opdualag 6 CTLA-4 Antigen 6 relatlimab 5 binimetinib 5 trametinib 4 Paclitaxel 4 dabrafenib 3 Taxes 3 Standard of Care 3 Pemetrexed 3 Introns 3 Interferon alpha-2 3 Gemcitabine 3 Carboplatin 3 Blood Specimen Collection 3 ulixertinib 2 sargramostim 2 lifileucel 2 lenvatinib 2 fludarabine phosphate 2 fludarabine 2 encorafenib 2 capivasertib 2 cabozantinib 2 atezolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Palliative Care × 30 days × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡